Secukinumab, a human immunoglobulin , represents a significant development in the approach of immune-mediated conditions . Its key mechanism of action involves specifically inhibiting Interleukin-17A , a cytokine linked in the development of conditions like psoriatic joint disease and scaling skin . By interfering with the IL-17A , Secukinumab exhi

MEDI-528, now recognized as enokizumumab, represents a novel medication targeting the IGF-1R , a key protein implicated in multiple dermatological ailments. Early clinical results suggest significant efficacy for the lessening of substantial itchy skin, particularly in individuals who have not benefited from conventional treatments . This monoclona